What if antibody precision is not enough?

Lytica is a Cambridge-based biotech company developing novel peptide conjugates for next-generation ADCs.

The secret to unlocking more effective ADCs is in the payload

Traditional antibody-drug conjugates combine two technologies into one: targeted antibodies and cytotoxic payloads.

At Lytica, we’re challenging that definition by building unique conjugates that imbue antibodies with new therapeutic properties.

Modular Platform

Our stapled peptide platform enables rapid exploration of ADC combinations

Accelerate drug development

Peptide-based conjugates are fast to develop because they are modular, making them easy to put together, break apart, and scramble.

Increase ADC technology compatibility

The modularity of peptides and the stabilizing properties of peptide stapling makes Lytica’s payloads highly compatible with existing antibody and linker technologies.

Unlock previously undruggable targets

Our conjugates allow us to drug new targets, opening up a new landscape of potential target combinations.

Our team

We’re leveraging our expertise in stapled peptides to push ADC technology forward


James LaTorre, CFA

Chief Executive Officer

Prior to co-founding Lytica, Jim was on the Board of Trustees at the Dana-Farber Cancer Institute and co-founded the firm Northern Cross which, over the course of nearly three decades, grew to manage over $60 billion of investor assets.

Rida Mourtada, PhD

President & Chief Scientific Officer

Rida has over a decade of research experience in the preclinical development of small peptide therapeutics in oncology & infectious disease. He received his doctorate from the Harvard-MIT Program in Health Sciences and Technology at MIT.

Loren Walensky, MD, PhD

Scientific Cofounder

Loren is Principal Investigator and Attending Physician in the Department of Pediatric Oncology at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Professor Pediatrics at Harvard Medical School, and Director of the Harvard/MIT MD-PhD Program.


John Bajacan
Scientist, Chemistry
Isabelle Hanna
Senior Research Associate, Biology
Daniel Cohen, PhD
Associate Principal Scientist, Protein Chemistry
Killian O'Brien, PhD
Senior Scientist, Biology
Lip Nam Loh, PhD
Associate Principal Scientist, Biology
Arianna Finnegan
Operations Manager
Jessica Beltrán
Director of Operations
Johannes Witt
Co-op Research Associate

Scientific Advisory Board

Robert Orlowski, MD, PhD

Florence Maude Thomas Cancer Research Professor and Director of the Myeloma Section, The University of Texas MD Anderson Cancer Center

Kenneth Anderson, MD, PhD

Kraft Family Professor of Medicine, Harvard Medical School Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute‍

Robert Lutz, PhD

CSO, Iksuda Therapeutics Former VP of Translational R&D, Immunogen

Marco Gottardis, PhD

Former VP of Oncology Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson

Steve Projan, PhD, FAAM

Former Head of the Infectious Diseases & Vaccines Innovative Medicines unit (iMED) at MedImmune Former VP and Global Head of Infectious Diseases at the Novartis Institutes for Biomedical Research

Joel Freundlich, PhD

Professor, Pharmacology, Physiology & Neuroscience New Jersey Medical School Rutgers University

James Balkovec, PhD

Principal at ChemTract Consulting Co-inventor of Caspofungin, the first glucan synthase inhibitor (GSi) for the treatment of serious fungal infections

Edward Ha, PhD

Head of ADC Innovation, Iksuda Therapeutics


Help us develop
ADCs of the future

Join our team

We partner with pharma leaders to amplify ADC therapeutic value using smart payloads

Partner with us

Discover more


Get in touch

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Lytica Therapeutics Inc.

840 Memorial Drive
Cambridge, MA 02139

Tel: 617-475-7374

Email: info@lyticatx.com